Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension
Evidence on Adverse Effects
Cough was more frequently observed as an adverse event in groups treated with ACEIs than in groups treated with ARBs. Withdrawals due to adverse events were modestly more frequent for groups receiving an ACEI rather than an ARB; this is consistent with differential rates of cough. No significant between-class differences were observed in the rates of any other commonly reported adverse events.
Note: When used during pregnancy, ACEIs, ARBs, and DRIs can injure or be fatal to the developing fetus.
- Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Comparative Effectiveness Review No. 34. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 11-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 2011. Available at: http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=696.
Your slide tray is being processed.